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Abstract: Levuglandins (LGs) and isolevuglandins (isoLGs), formed by rearrangement of 
endoperoxide intermediates generated through the cyclooxygenase and free radical induced 
oxidation of polyunsaturated fatty acids (PUFAs), are extraordinarily reactive, forming 
covalent adducts incorporating protein lysyl ε-amino groups. Because they accumulate, 
these adducts provide a dosimeter of oxidative injury. This review provides an updated and 
comprehensive overview of the generation of LG/isoLG in vitro and in vivo and the 
detection methods for the adducts of LG/isoLG and biological molecules in vivo. 
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1. Introduction 
Lipids are essential cell membrane components. They incorporate abundant polyunsaturated fatty 
acids (PUFAs) that are particularly susceptible to oxidative damage. In view of the ready oxidizability 
of PUFAs and the aerobic environment we live in, it is understandable that lipid oxidation plays a key 
role in human health. Increasing substantial evidence suggests that lipid oxidation is involved in the 
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development of many chronic diseases. This has stimulated worldwide efforts to elucidate the 
mechanisms and pathological consequences of lipid oxidation [1-3]. 
Levuglandins (LGs) and isolevuglandins (isoLGs)—also referred to as the “isoketals” [4]—are  
γ-ketoaldehydes that are formed by rearrangement of endoperoxide intermediates generated through the 
cyclooxygenase and free radical-induced oxidation of arachidonates. The γ-ketoaldehyde functionality 
of the LGs and isoLGs makes them extraordinarily reactive towards primary amino groups in 
biomolecules. LGs and isoLGs react with the ε-amino groups of lysyl residues in proteins to produce 
covalent adducts with greater avidity than most other lipid oxidation products, e.g., 4-hydroxynonenal 
(4-HNE) or malondialdehyde (MDA) [4]. This feature makes covalent LG/isoLG adducts attractive as 
biomarkers to evaluate oxidative injury in the tissues. LGs/isoLGs initially react with primary amino 
groups to form in seconds Schiff base adducts which are transformed to pyrrole adducts in minutes. 
However, these highly alkylated pyrroles are chemically sensitive compounds in the presence of 
oxygen [5] and are further oxidized in a few hours to stable end products, lactams and hydroxylactams 
(HLs) [6]. First detected in vivo by immunoassays, quantitative analysis of LG/isoLG protein adducts 
was also achieved by LC-MS after proteolysis to LG/isoLG-lysine derivatives that incorporate the 
lysine ε-amino group into LG/isoLG-derived lactams. Salomon et al. reported that isoLGE2-protein [7], 
iso[4]LGE2-protein [8] and iso[7]LGD2-protein [9] adducts are generated upon oxidation of LDL  
in vitro. Formation of isoLG protein adducts in vivo has also been confirmed by a variety of 
immunological and mass spectrometric methods [10,11]. The levels of isoLG-protein adducts are 
elevated in diseases associated with oxidative injury [11]. 
This review will describe levuglandins and isolevuglandins with emphasis on their generation, 
protein modification and identification of the novel and stable compounds produced during the 
oxidation of PUFAs which could serve as unique indicators for PUFA-associated oxidative injuries, 
and provide valuable insights into the pathophysiology of diseases related to oxidative stress. 
2. Generation of Levuglandins and Isolevuglandins 
Arachidonic acid, a linear twenty carbon methylene interrupted polyunsaturated fatty acid 
(C20:4ω6), is oxidatively transformed by two different enzymatic metabolic pathways catalyzed by 
cyclooxygenase and lipoxygenase, resulting in a large array of biologically active oxidized 20 carbon 
fatty acids, collectively called eicosanoids. Besides these enzymatic pathways, growing evidence has 
also suggested the existence of a free radical-induced metabolic pathway which further greatly expands 
the family of eicosanoids [9,12-16]. 
2.1. Enzymatic Pathways 
Cyclooxygenase can catalyze a unique transformation, in which two molecules of oxygen  
are chemoselectively and stereospecifically added to a molecule of AA to produce prostaglandin 
endoperoxide G2 (PGG2). This PGG2 is a highly reactive molecule which undergoes chemoselective 
reduction catalyzed by hydroperoxidase, to produce the unstable prostaglandin endoperoxide H2 
(PGH2, t1/2 = 5 min at 37 °C in aqueous solution) [17]. PGH2 is a pivotal intermediate in regulating a 
wide variety of cellular activities and undergoes enzymatic and non enzymatic (solvent-induced) 
rearrangements to provide an array of physiologically active molecules. Lipoxygenases, on the other 
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hand, can catalyze the conversion of polyunsaturated fatty acids (PUFAs) into the corresponding fatty 
acid hydroperoxides by insertion of a molecule of oxygen, for example, soybean lipoxygenase, can 
generate 13-hydroperoxyoctadecadienoate (13-HPODE) from linoleic acid (LA) and 15-hydroperoxy-
eicosatetraenoate (15-HPETE) from AA. 
The major products of the enzymatic rearrangement of PGH2 are prostaglandin E2 (PGE2), 
prostaglandin D2 (PGD2), prostaglandin and thromboxane A2 (TXA2). The solvent-induced 
nonenzymatic conversion also results in formation I2 (PGI2) from PGE2 and PGD2. Reduction of PGH2 
results in prostaglandin F2α (PGF2α) [18,19]. Enzyme-induced skeletal rearrangement of the strained 
bicyclic ring system of PGH2 results in PGI2 and TXA2. 12-Hydroxyheptadeca-5(Z),8(E),10(E)-trienoic 
acid (HHT) and malondialdehyde (MDA) are produced as a result of fragmentation of PGH2 [20,21]. 
These molecules exert various physiological effects that are often complimentary to each other [22-27]. 
Salomon [28,29] discovered that a novel alternative rearrangement of PGH2 also occurs that 
produces two γ-ketoaldehydes, which were named levuglandin E2 (LGE2) and levuglandin D2 (LGD2) 
because they are derivatives of levulinaldehyde with prostanoid side chains [7]. Detailed mechanistic 
studies revealed that levulinaldehyde was generated as a result of a 1,2-hydride shift during the 
cleavage of three bonds in a concerted fashion with a polarized transition state during the rearrangements 
of endoperoxide in aqueous solution [30,31]. 
Levuglandins are sensitive vinylogous β-hydroxy carbonyl compounds which readily undergo 
dehydration leading to their anhydro analogs AnLGE2 and AnLGD2 as shown in Scheme 1. 
Scheme 1. Decomposition of PGH2: Generation of levuglandins, anhydrolevuglandins and 
Δ9-levuglandins. 
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The propensity of LGD2 to undergo dehydration has precluded its isolation as well as total  
synthesis [29]. The C10-C11 double bond also migrates to form the more stable conjugated isomers, 
Δ9-LGE2 and Δ9-LGD2 [30]. Convergent asymmetric total syntheses of LGE2 and AnLGD2 were 
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developed that not only confirmed their structures but also provided adequate amounts of these 
complex AA metabolites for thorough chemical and biological studies [32,33]. 
2.2. Free Radical Pathways 
Generation of stereo and structural isomers of PGs was firstly recognized in a study to quantify the 
biologically relevant PGs generated enzymatically through the action of COX during AA metabolism [34]. 
However, the biological significance of this pathway, now called the isoprostane pathway, was ignored 
for two decades. 
In the early 90s, researchers reported that an in vivo non enzymatic generation of PGH2 isomers 
occurs in humans resulting in the generation of large amounts of PG isomers upon AA metabolism [12]. 
The in vitro formation of significant amounts of 8-epi-PGF2α  isomers as well as other isomers of PGs, 
named isoprostanoids, in aged human plasma, first prompted the rediscovery of this nonenzymatic 
pathway (isoprostane pathway). Further studies showed the formation of these isoprostonoids in vivo [13]. 
The generation of large amounts of 8-epi-PGF2α and other isoprostanoids in the plasma of mice treated 
with free radical initiators like CCl4 and diquat, further supported a free radical peroxidative 
mechanism [14]. The fact that the generation of these isoprostanoids could not be suppressed in vivo, 
even after application of cyclooxygenase inhibitors, strongly supports the alternative, free radical 
pathway [35]. The same researchers also reported that isoprostanes that are PGD2- and PGE2-like 
compounds (D2/E2-IsoPs) were found to be generated in vivo as phospholipid esters through  
non-enzymatic rearrangements of stereo and structural isomers of PGH2 derivatives (isoprostane 
endoperoxides) that are produced through free radical-induced cyclooxgenation of arachidonyl 
phosphatidylcholine (AA-PC) [36]. 
The formation of LGs during nonenzymatic rearrangement of PGH2 to PGs was discovered by 
Salomon et al. [37]. Based on these observations, they proposed that nonenzymatic in vivo generation 
of LG isomers from endoperoxides could occur during free radical-induced oxidation [7] (Scheme 2). 
The rearrangement of the 2-lysophosphatidylcholine (PC) ester 8-epi-PGH2-PC delivers 8-epi-LGE2-
PC. The 8-epi-LGE2-PC isomer produced in this way is expected to differ in configuration at carbon 
C8 from that produced by the rearrangement of PGH2 generated by the cyclooxygenase pathway. It is 
also expected to be racemic. However, an immunochemical assay (vide infra) for protein-bound  
LG-derived pyrrole would not differentiate between cyclooxygenase-derived or nonenzymatically 
produced LG isomers as the stereogenic centers at both C8 and C9 in 8-epi-LGE2-PC are destroyed 
during LGE2-pyrrole formation. 
Furthermore, because hydrogen atom abstraction readily occurs nonregioselectively at any doubly 
allylic methylene, the free radical pathway can not only produce a stereoisomer mixture of 
levulinaldehyde derivatives with PG side chains, i.e., isoLGs, but also levulinaldehyde derivatives with 
non-prostanoid side chains, i.e., iso[n]LGs. Non-regioselective hydrogen atom abstraction from the 7, 
10, and 13-positions of an arachidonyl ester produces three regioisomeric pentadienyl radicals 
(Scheme 2). These then react with molecular oxygen to afford four regioisomeric peroxyeicosa-
tetraenoyl radicals that undergo peroxyradical cyclization [38] to deliver four structurally isomeric 
endoperoxides. Each endoperoxide rearranges to form two LGs or iso[n]LGs, designated as E series if 
the acetyl substituent is nearer than the formyl substituent to the carboxyl group or as D series if the 
formyl is nearer than the acetyl to the carboxyl. For iso[n]LGs, the bracketed integers indicate the 
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length of the carboxylic side chain [7]. For example, hydrogen atom abstraction from the 10-position 
of AA-PC followed by cyclization of an intermediate 8- radical could lead to iso[4]PGH2-PC and  
then iso[4]LGE2-PC, where the number in brackets signifies the length of the carboxylic side chain 
appended to a common 2,3-dioxabicyclo[2.2.1] heptane or levulinaldehyde core. 
Scheme 2. Generation of isolevuglandins and isolevuglandin-protein adducts during free 
radical oxidation of AA and AA-esters. 
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The terms “isoketal or IsoK” were used [39] as alternatives to the original isoLG nomenclature [7] 
“to distinguish them from levuglandins formed by rearrangement of the cyclooxygenase endoperoxide 
intermediate, PGH2”. However, such a distinction is erroneous because the exact same levuglandin 
molecules, LGE2 and LGD2, are generated by both the cyclooxygenase and isoprostane pathways. The 
difference between the pathways is that stereo and structural isomers are cogenerated with LGE2 and 
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LGD2 in free radical-induced autoxidation of arachidonates. On the other hand, it is important  
to emphasize the difference between stereoisomers of levuglandins and structural isomers of 
levuglandins. In the nomenclature, this distinction is reflected in the dichotomy of isoLGs and 
iso[n]LGs. Thus, for example, LGE2, one of the stereoisomers designated collectively as isoLGE2, is a 
product of both the COX and isoprostane pathways whereas all stereoisomeric iso[4]LGE2s are only 
produced through the isoprostane pathway. The alternative names, 15-E2-IsoK and 12-E2-IsoK, 
respectively, do not convey this fundamental difference. 
Studies reveal that myeloperoxidase (MPO) serves as an enzymatic catalyst for initiation of lipid 
peroxidation and lipoprotein oxidation in vivo [40]. MPO is an abundant heme protein secreted by 
phagocytes in response to stimulation [41]. MPO [42] and its distinct products [HOCl-damaged 
proteins [43] and 3-chlorotyrosine [44] are enriched in human atherosclerotic aortic intima and LDL 
recovered from atheroma. MPO uses H2O2 together with low molecular weight cosubstrates like 
chloride [45], tyrosine [46],and nitrite (NO2−) [47,48] to generate a variety of reactive oxidants and 
diffusible radical species [49,50]. With the MPO-H2O2-NO2− catalytic system, Salomon group 
confirmed the in vitro generation of isoLGs, isoLGE2, iso[4]LGE2 and iso[7]LGE2, during the free 
radical-induced peroxidation of AA-PC. These facts further confirmed the feasibility of the 
“isolevuglandin pathway” in nonenzymatic AA metabolism. 
2.3. Free Radical Oxidation of Docosahexaenoic Acid (DHA) 
Docosahexaenoic acid (C22:6ω3) (DHA), a member of ω-3 PUFAs, is an essential requirement for 
the function and development of the human brain and retina [51]. While the content of DHA in human 
plasma LDL is low, the DHA content in brain and retina ranges from 20%–60% of total fatty acid 
content and is present estified in phospholipids [52]. Although the exact role of DHA is not clear, 
deficiency of DHA is associated with the abnormalities in brain function [53]. Similar to other PUFAs, 
DHA is readily oxidized in vitro because of the presence of six homoallylic double bonds. Considering 
of the structural similarity between AA and DHA, analogue isoprostanes could be generated upon the 
free radical-induced peroxidation of DHA. Enhanced lipid oxidation has been reported as a 
consequence of oxidative injuries or decrease in antioxidant capacity in human brain and retina as 
measured using the simple thiobarbituric acid (TBA) test [54,55]. The free radical-induced peroxidation 
of DHA might play an important role in the pathogenesis of neurodegenerative diseases, e.g., 
Alzheimer’s disease, Parkinson’s disease, etc. [56-58]. 
Despite the complications involved, identification of DHA peroxidation products have been carried 
out by several research groups [59,60].The quantification of such peroxidation products might provide 
a unique marker of oxidative injury in human brain and retina, and also a better understanding of their 
biological roles. In analogy to the free radical-induced mechanism that produces F2-isoprostanes from 
arachidonic acid, F4-C22-isoprostanes, 22-carbon analogues of PGF2α, were generated during the in vitro 
nonenzymatic peroxidation of DHA [59]. The mechanism of the formation of F4-C22-isoprostanes 
(Scheme 3) involves generation of DHA radicals at doubly allylic methylene positions, addition of 
molecular oxygen, followed by the formation of bicyclic endoperoxide intermediates from the 
resulting peroxyl radicals. The bicyclic endoperoxide intermediates are then reduced to form  
F4-C22-isoprostanes. It is known from previous studies [61] that such bicyclic endoperoxides can also 
readily undergo another kind of rearrangement to produce levuglandin-like products. 
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Scheme 3. F4-C22-isoprostane and C22-isolevuglandin (11-isoLGE4) generation from 
nonenzymatic peroxidation of docosahexaenoic acid (DHA). 
O
O
COOH
O
O
O
O
O
O
COOH
69
12
-9-H
15 18
COOH
9
12
15 18
COOH612
15 18
-6-H
COOH6
9
12
15
-18-H
COOH
9
12
15 18
COOH6
9
12
15 18
COOH6
9
12
15 18
COOH6
9
12
15
O O O O O O
OO
COOH
OH
COOH
OH
OH OH
COOH
3
33
COOH
COOH
OH
COOH
OH
OH OH
COOH
3
33
HO
HO
HO
HO
HO
HO HO
HO
4-Series 7-Series 11-Series 20-Series
COOH6
9
12
15 18
-12-H -15-H
COOH6
9
15 18
COOH6
9
12
18
COOH6
15 18
COOH6
9
15 18
COOH6
9
18
COOH6
9
18
O O
OO OOOO
12
O
O
O
O
O
O
O
O
COOH
OH
OH
COOH
23
2
COOH
OH
OH
COOH
2
HO
HO
HO
HO HO
HO
14-Series 10-Series 13-Series 17-Series
COOH
OH
2
2
COOH
OH
2
COOH
OH
3 COOH
OHHO
HO
nonenzymatic
rearrangement
[H] [H][H] [H]
DHA
O2 O2 O2 O2
DHA
O2 O2 O2 O2
[H] [H][H] [H]
O
O
COOH
OH
COOH
OH
O
O
C22-11-isoLGE4  
 
Molecules 2011, 16 
 
5340
3. Detection of Biological Adducts of Isolevuglandins 
3.1. Immunological Detection of Protein Adducts of LGs and IsoLGs 
Previous studies by Salomon et al. had shown that the γ-ketoaldehyde functional array in LGE2 has 
an extraordinary proclivity towards rapid covalent adduction with proteins. For examples, human 
serum albumin binds 10 equivalents of LGE2 within 1 min [62]. Consistent with their earlier result, 
Brame confirmed the rapid consumption of LGE2 (t1/2 = 20 s) upon exposure to bovine serum albumin 
using mass spectrometry [63]. LGE2 reacts with ε-lysyl amino groups of proteins to form Schiff base 
adducts [64]. Pyrrole derivatives are then generated upon rapid cyclization and dehydration [65]. 
Further oxidation delivers lactam and hydroxylactam stable end products [63]. Pyrrole and Schiff-base 
derivatives of phospholipids are generated by analogous reactions with LGE2 stereoisomers with 
phosphatidyl ethanolamine [66]. 
Because LGs are rapidly sequestered by covalent adduction with proteins, Salomon et al. developed 
assays to detect their presence in vivo using antibodies that would recognize their protein adducts [67]. 
Existence of LGE2-protein adducts in vivo was first detected in human cerebral vasculature using 
polyclonal rabbit antibodies [10]. However, they noticed in these studies that they could not distinguish 
between a cyclooxygenase formation or a possible alternative free radical-induced autoxidative 
biogenesis for these LGE2-protein adducts in vivo. Thus, Salomon predicted that epitopes that would 
be recognized by LGE2-protein adduct antibodies could be generated by free radical-induced 
autoxidation of arachidonyl phospholipids [68]. Experimental evidence supporting this hypothesis was 
first provided by the demonstration that LGE2-protein adducts are generated upon free radical-induced 
autoxidation of low-density lipoprotein in vitro [7]. Thus, antibodies against LGE2-protein adducts were 
useful tools for detecting products of the isoprostane pathway for in vitro systems that do not contain 
cyclooxygenase activity. The discovery of isolevuglandins (also referred to as isoketals) exploited 
rabbit polyclonal antibodies against LGE2-protein adducts to detect the production of LGE2 through 
free radical-induced oxidation of LDL in vitro [7]. Further evidence supporting the conclusion that 
these immunoreactive protein modifications were derived from LGE2 stereoisomers (isoLGs) was then 
secured by mass spectroscopic analysis (vide infra) of the modified lysine excised from LDL protein 
through exhaustive proteolysis [63]. 
It is important to emphasize that distinguishing LGE2 production through the two entirely different 
biochemical pathways, COX and isoprostane, is a redoubtable challenge. The LGE2-protein adduct 
immunoreactivity detected in human cerebral vasculature was cited as an example of the localization 
of “isoK adducts” [69]. However, antibodies against LGE2-protein adducts cannot distinguish the 
operation of a free radical-promoted isoLG (isoK) biogenesis from a COX mediated biosynthesis 
through the levuglandin pathway in vivo unless the COX activity has been inhibited. 
Structural isomers of LGE2, designated collectively as iso[n]LGE2s, are unique products of the free 
radical pathway (Scheme 2). Therefore, to provide a valuable tool for the unambiguous assessment 
isoLG production in vivo, antibodies against iso[4]LGE2-protein adducts [8] were raised and used to 
demonstrate the presence of isolevuglandins in human blood [11]. Antibodies raised against 
iso[7]LGD2-protein adducts further confirmed the operation of the isolevuglandin pathway in vivo [9]. 
The mean levels of the iso[4]LG and iso[7]LG adducts, as well as those detected with antibodies raised 
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against LGE2-protein adducts [10], are elevated in plasma from individuals with atherosclerosis 
compared to individuals with no cardiovascular disease. 
3.2. Mass Spectrometric Detection of Protein Adducts of LGs and IsoLGs 
Mass spectrometry is increasingly being employed to identify the structures of biomolecules from 
in vivo samples, especially of proteins (proteomics), lipids (lipidomics) and metabolites (metabolomics). 
This is mostly owing to the discovery of soft ionization techniques, such as electrospray ionization 
(ESI) [70] and matrix-assisted laser desorption ionization (MALDI) [71,72] over 20 years ago. Also, 
the design of new more robust instruments and user-friendly software that allows multiple data 
processing and analysis have made mass spectrometry an accessible technique for the study of 
biomolecules in general. Briefly, organic mass spectrometry is an analytical technique which allows 
measuring the molecular weight and relative abundances of an analyte. In addition, generally by using 
tandem mass spectrometry, structural information of molecules can also be obtained. The most 
common ionization methods used in the analysis of phospholipids are electrospray ionization (ESI) 
and matrix-assisted laser desorption ionization (MALDI). These soft ionization methods produce 
almost no fragmentation, and allow the ionization of non-volatile and thermolabile samples. Usually, 
this is an advantage, especially in the analysis of mixtures, but only information about the molecular 
weight of the compounds can be obtained. However, it is possible to induce the fragmentation of the 
sample ions, commonly by using collision induced dissociation (CID). In this technique called tandem 
mass spectrometry, MS/MS, fragmentation of a selected ion by collision with an inert gas is induced 
and the product ions are analyzed. High sensitivity analysis, usually in the fmol range, of complex 
sample mixtures and the capacity of coupling with separation techniques, namely liquid chromatography 
(LC) are other advantages of this technique. It is beyond the scope of this review to give a 
comprehensive outline of the mass spectrometry fundamentals. Encompassing this emergent trend, 
mass spectrometry is becoming increasingly important in phospholipid oxidation research. One of the 
main reasons for this, other than the increasing spread of mass spectrometers, is that interpreting mass 
spectra of oxidized phospholipids is usually straightforward [73,74]. 
LC-ESI/MS/MS analysis of the lysyl lactam adduct of LGE2 shows a parent ion at m/z 479.3 and a 
daughter ion at m/z 84.1 that arises from the lysyl moiety [63]. All isoLG-derived lysyl lactams can 
deliver parent and daughter ions with these same exact masses (Scheme 4). LC-ESI/MS/MS analysis 
of the amino acids obtained by exhaustive proteolysis of isoLG-apoB adducts, generated upon 
oxidation of LDL in vitro, indicated a complex mixture of products exhibiting the m/z 479.3–84.1 
transition as expected for a family of structurally isomeric isoLG-derived lysyl lactams. As mentioned 
above, this experiment confirmed their earlier finding, based on immunological evidence, that 
isolevuglandins are generated through free radical-induced oxidation of LDL in vitro [7]. The LC-MS 
technique was also applied to the quantitative analysis of lysyl lactams obtained by exhaustive 
proteolysis of plasma proteins [75]. The lactam derivatives of isoLGE2 prepared from [3H2,13C6]-lysine 
were used as an internal standard. This analytical method provides a convenient measure of total  
LG and isoLG protein adducts, but does not distinguish COX products, i.e., levuglandins, from 
isolevuglandins (isoketals). 
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Scheme 4. MS/MS fragmentation of isolevuglandin-derived lysyl lactams. 
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The Schiff base adducts generated initially in the reaction of LGE2 with proteins can be stabilized 
by reduction with sodium borohydride. Subsequent exhaustive proteolysis gives reduced adducts of 
lysine that exhibit a dehydrated parent ion at m/z 467.3 [64]. MS/MS analysis of this ion produces  
a daughter ion with m/z 321.2 that probably is a protonated tetrahydrofuryl ion generated by 
intramolecular nucleophilic displacement of lysine. 
All isoLG-derived reduced Schiff base adducts of lysine can give parent and daughter ions with 
these same exact masses. Recently, the LC-ESI/MS/MS technique was applied to the quantitative 
analysis of reduced Schiff base adducts obtained by exhaustive proteolysis of liver proteins from rats 
treated with CCl4, a model of oxidant injury to liver [75]. Schiff base adduct levels prior to base 
treatment were barely detectable. Apparently, more than 97% of the Schiff base adducts were 
incorporated in phospholipid esters. Because only free AA is a substrate for COX, these phospholipid 
Schiff base adducts are unique products of free radical-induced cyclooxygenation. The provenance of 
Schiff base adducts that are not incorporated in phospholipid esters must be determined independently 
because they can also be generated through the COX pathway [76]. 
A remarkable dichotomy between the Schiff base and lactam adducts was observed in these 
experiments. While the isoLG-derived Schiff base derivatives of proteins were present in the form of 
phospholipid esters, the lactam derivatives were present as free acids [75]. IsoLG-Schiff base adducts 
are intermediates that are converted into pyrroles and then lactams. Three possible alternative 
explanations for the preferential incorporation of Schiff base adducts into phospholipid esters are:  
(1) Schiff base esters are far superior substrates for esterases than lactam esters; (2) Cyclization of 
Schiff bases to give pyrroles is strongly disfavored by the membrane environment to which 
phospholipids are anchored and (3) Oxidation of pyrroles to give lactams is strongly disfavored by the 
membrane environment. In other words, the last two alternatives mean that: (1) Pyrrole formation from 
a Schiff base or (2) Pyrrole oxidation occurs much more readily for the free acid adducts than for the 
phospholipid adducts. It seems likely that investigation of this dichotomy will provide valuable 
insights into the unique environment present at the membrane/water interface. 
Except for detection of protein adducts, Salomon et al. [77,78] report the detection in vivo  
and quantitative analysis of LG/isoLG adducts that incorporate the primary amino group of 
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phosphatidylethanolamines (PEs) into LG/isoLG-derivsed hydroxylactams (HLs) using HPLC-MS/MS. 
In pilot clinical studies, the levels of isoLG-PE-HL in plasma from Age-related Macular Degeneration 
(AMD) patient samples are elevated compared with those in plasma from control samples. And the 
levels of isoLG-PE-HL are significantly elevated in murine model of alcoholic liver disease. 
4. Conclusions 
In summary, the generation of levuglandin/isolevuglandin upon free radical-induced peroxidation of 
polyunsaturated fatty acid plays important roles in the pathology of diseases related to oxidative stress. 
The discoveries of adducts of LG/isoLG and biological molecules will provide clues about the 
biomarkers in the field of oxidative injuries.  
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